Flomoxef Sodium

- Overview
  - Flomoxef Sodium is a β-lactam inhibitor and member of the oxacephem family and exhibits antibiotic properties. It has been used for respiratory infections and bone diseases (ie osteoporosis). It was synthesized in 1982 by Shionogi & Co, Osaka, Japan in order to overcome disulfiram actions.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Flomoxef Sodium is a β-lactam inhibitor that acts by inhibiting cell-wall synthesis. This is performed by binding to penicillin-binding proteins which prevents the transpeptidation step of peptidoglycan synthesis in bacterial cell walls, leading to the inhibition of cell-wall biosynthesis.
- Properties
  - CAS Number
    
    92823-03-5
    
    Molecular Formula
    
    C15H18F2N6NaO7S2
    
    Molecular Weight
    
    519.451
    
    Appearance
    
    White or off-white powder
    
    Other Properties
    
    Source: Synthetic
    
    Storage
    
    -20 °C
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: Flomoxef Sodium is effective for Gram-negative and Gram-positive bacteria including MRSA. It is also effective for Nocardia.
    
    Microbiology Applications: Flomoxef is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative MIC values include:
    
    B. fragilis 0.5 µg/mL – ≥ 128 µg/mL
    MRSA 4 µg/mL - ≥ 16 µg/mL